Anavex Life Sciences Corp. (AVXL)
Nasdaq: AVXL · Biological Products, (No Diagnostic Substances) · New York, NY · filing with the SEC since 2005
Filings
205 filings since 2017 beside 126 insider forms · Large accelerated filer and smaller reporting company · read from EDGAR on Nov 13, 2026Due nextLarge accelerated filer and smaller reporting company
10-K
Annual report for the fiscal year ending Sep 30, 2026Large accelerated filers have 60 days after the fiscal year ends.
by Nov 29, 2026
10-Q
Quarterly report for the quarter ending Dec 31, 2026Large accelerated filers have 40 days after the quarter ends; quarter ends are taken to the month end.
by Feb 9, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 56 days after the quarter ended. The proxy statement was last filed Apr 25, 2025.
Filings a yearinsider forms included
2526372522283367
2026 counts to Nov 13, 2026.
Officer or director change (8-K item 5.02): 7 times in the last 36 months, the newest Nov 3, 2026.Listing warning from its exchange (8-K item 3.01): 1 time in the last 36 months, the newest May 22, 2026.SEC letters: 2 in the last 36 months, the newest Jul 21, 2025.A late-filing notice, Form NT 10-Q, filed Aug 10, 2026.A late-filing notice, Form NT 10-Q, filed May 11, 2026.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Nov 2, 2026
8-K items 5.02, 8.01, 9.01
Officer or director change; Other event · Current report
Oct 28, 2026
40 of 205 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.